Bionano Genomics, Inc. Common Stock (BNGO) — Analysis Summary
Bionano Genomics, Inc. Common Stock (BNGO) has a market cap of $12.74M with year-over-year revenue growth of -7.4%. Net margin stands at -92.6%. The stock trades at a P/E ratio of -0.4.
Key Takeaways
- Revenue changed -7.4% year-over-year
- Net margin of -92.6%
- P/E ratio of -0.4
Compared to other companies in the LABORATORY ANALYTICAL INSTRUMENTS sector, BNGO posted revenue growth of -7.4% and trades at a P/E of -0.4.
Bionano Genomics, Inc. Common Stock (BNGO)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -114.0% — severe operating losses
Net margin at -109.9% — losses exceed revenue (possible one-time charges)
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Employees
97
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.